“Group B, small sample sample size but looking blockbuster 3 patients, 2 complete response, 1 stable disease - which may yet get upgraded (believed pseudo progression).”
This is indeed a most impressive result. If the stable disease result gets upgraded to a third complete response, it will mean a 100% positive result, albeit from a small sample of three.
This kind of result is truly eye opening. If this is replicated in further patients, the azer cell plus IL2 combo alone should be worth billions of dollars to the company. Never mind CF33 and everything else.
Ann: Three Complete Responses in Azer-Cel Phase 1b Trial, page-251
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.8¢ |
Change
0.006(9.68%) |
Mkt cap ! $499.7M | |||
| Open | High | Low | Value | Volume |
| 7.3¢ | 8.1¢ | 6.7¢ | $14.56M | 194.2M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 605784 | 6.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.8¢ | 159880 | 2 |
View Market Depth
| Last trade - 16.10pm 02/09/2024 (20 minute delay) ? |
| IMU (ASX) Chart |